CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.15 USD
-0.04 (-3.36%)
Updated Sep 23, 2024 04:00 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Brokerage Reports
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 1 - 20 ( 158 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-904 Program Update by YE24; 2Q24 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; CX-904 Ph 1 Update in YE:24, CX-2051 Data in 1H:25
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One Step Ahead; New Developments in Cancer Resistance
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from KOL Panels at Our Immune Cell Engager Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from HCW Immune Cell Engager Conference; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-904 Ph 1a Initial Data Encouraging, Upgrading to OUTPERFORM, PT to $8
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing Initial CX-904 Data; More Phase 1a Data YE24; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Phase 1a CX-904 Data in 2H24; 2023 Financial Results; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; CX-904 Ph 1 Data in 2H:24; Additional Programs Move to Ph 1
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Two Programs to Enter Clinic in 1H:24; CX-904 Data in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Crucial Clinical Datasets in 2024; 3Q23 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Worldwide Rights Regained for CD71-Targeted ADC; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M